pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2008-0-2-5-14pulmo-1770Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALХроническая обструктивная болезнь легких и сопутствующие заболеванияChronic obstructive pulmonary disease and co-morbiditiesЧучалинА. Г.ChuchalinA. G.
Москва
ФГУ НИИ пульмонологии РосздраваRussian Federation20082804200802514Copyright © Чучалин А.Г., 20082008Чучалин А.Г.Chuchalin A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1770
.
.
ReferencesBuch P., Friberg J., Scharling H. et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur. Respir. J. 2003; 21 (6): 1012–1016.Buch P., Friberg J., Scharling H. et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur. Respir. J. 2003; 21 (6): 1012–1016.Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients for acutely exacerbated chronic obstructive pul# monary disease. Am. J. Med. 1995; 98 (3): 272–277.Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients for acutely exacerbated chronic obstructive pul# monary disease. Am. J. Med. 1995; 98 (3): 272–277.Kleiger R.E., Senior R.M. Long#term electrocardiographic monitoring of ambulatory patients with COPD. Chest 1974; 65: 483.Kleiger R.E., Senior R.M. Long#term electrocardiographic monitoring of ambulatory patients with COPD. Chest 1974; 65: 483.Shih HT., Webb C.R., Conway W.A. et al. Frequency and significance of cardiac arrhythmias in COPD. Chest 1988; 94 (1): 44–48.Shih HT., Webb C.R., Conway W.A. et al. Frequency and significance of cardiac arrhythmias in COPD. Chest 1988; 94 (1): 44–48.Bittar G., Friedman H.S. The arrhythmogenicity of theo# phylline. A multivariate analysis of clinical determinants. Chest 1991; 99 (6): 1415–1420.Bittar G., Friedman H.S. The arrhythmogenicity of theo# phylline. A multivariate analysis of clinical determinants. Chest 1991; 99 (6): 1415–1420.Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta – agonists in patients with asthma and COPD: a meta#analysis. Chest 2004; 125 (6): 2309–2321.Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta – agonists in patients with asthma and COPD: a meta#analysis. Chest 2004; 125 (6): 2309–2321.Incalzi R.A., Pistelli R., Cocchi A. et al. Cardiac arrhythmias and left ventricular function in respiratory failure from chronic COPD. Chest 1990; 97 (5): 1092–1097.Incalzi R.A., Pistelli R., Cocchi A. et al. Cardiac arrhythmias and left ventricular function in respiratory failure from chronic COPD. Chest 1990; 97 (5): 1092–1097.Cheong T.H., Magder S., Shapiro S. et al. Cardiac arrhyth# mias during exercise in severe chronic obstructive pul# monary disease. Chest 1990; 97 (4): 793–797.Cheong T.H., Magder S., Shapiro S. et al. Cardiac arrhyth# mias during exercise in severe chronic obstructive pul# monary disease. Chest 1990; 97 (4): 793–797.Salpeter S., Ormiston T., Salpeter E. Cardioselective beta# blocker use in patients with revesible airway disease. Cochrane Database Syst. Rev. 2001; 2: CD002992.Salpeter S., Ormiston T., Salpeter E. Cardioselective beta# blocker use in patients with revesible airway disease. Cochrane Database Syst. Rev. 2001; 2: CD002992.Ind P.W., Dixon C.M., Fuller R.W., Barnes P.J. Anticholin# ergic blockade of beta#blocker – induced bronchoconstric# tion. Am. Rev. Respir. Dis. 1989; 139 (6): 1390–1394.Ind P.W., Dixon C.M., Fuller R.W., Barnes P.J. Anticholin# ergic blockade of beta#blocker – induced bronchoconstric# tion. Am. Rev. Respir. Dis. 1989; 139 (6): 1390–1394.Behar S., Panosh A., Reicher H. et al. Prevalence and prog# nosis of COPD among 5839 consecutive patients with acute myocardial infarction. Sprint Study Group. Am. J. Med. 1992;93 (6): 637–641.Behar S., Panosh A., Reicher H. et al. Prevalence and prog# nosis of COPD among 5839 consecutive patients with acute myocardial infarction. Sprint Study Group. Am. J. Med. 1992;93 (6): 637–641.Man S.F. COPD as a risk factor for cardiovascular morbidi# ty and mortality. Proc. Am. Thorax Soc. 2005; 2 (1): 8–11.Man S.F. COPD as a risk factor for cardiovascular morbidi# ty and mortality. Proc. Am. Thorax Soc. 2005; 2 (1): 8–11.Jousilahti P., Vartianen E., Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348 (9027): 567–572.Jousilahti P., Vartianen E., Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348 (9027): 567–572.Triboulloy C., Rosinaru D., Mahjoub H. et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population – based study. Eur. Heart. J. 2008;29 (3): 339–347.Triboulloy C., Rosinaru D., Mahjoub H. et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population – based study. Eur. Heart. J. 2008;29 (3): 339–347.Dahl M., Vestbo J., Lange P. et al. C#reactive protein as a predictor of prognosis in COPD. Am. J. Respir. Crit. Care Med. 2007; 175: 250–255.Dahl M., Vestbo J., Lange P. et al. C#reactive protein as a predictor of prognosis in COPD. Am. J. Respir. Crit. Care Med. 2007; 175: 250–255.Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstruc# tive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998;157 (6, pt. 1): 1791–1797.Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstruc# tive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998;157 (6, pt. 1): 1791–1797.van Vliet M., Spruit M.A., Verleden G. et al. Hypogonadism, quadriceps, weakness, and exercise intolerance in COPD. Am. J. Respir. Crit. Care Med. 2005; 172: 1105–1111.van Vliet M., Spruit M.A., Verleden G. et al. Hypogonadism, quadriceps, weakness, and exercise intolerance in COPD. Am. J. Respir. Crit. Care Med. 2005; 172: 1105–1111.
The authors declare that there are no conflicts of interest present.